[Castleman's disease in the rheumatological practice].

[1]  M. Dougados,et al.  A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases , 2022, RMD Open.

[2]  S. Aoki,et al.  Castleman disease and TAFRO syndrome , 2022, Annals of Hematology.

[3]  P. Fenaux,et al.  USAID Associated with Myeloid Neoplasm and VEXAS Syndrome: Two Differential Diagnoses of Suspected Adult Onset Still’s Disease in Elderly Patients , 2021, Journal of clinical medicine.

[4]  B. Damania,et al.  Castleman disease , 2021, Nature Reviews Disease Primers.

[5]  K. Notohara,et al.  Investigation of IgG4‐positive cells in idiopathic multicentric Castleman disease and validation of the 2020 exclusion criteria for IgG4‐related disease , 2021, Pathology international.

[6]  S. Mukherjee,et al.  Efficacy and safety of regimens used for the treatment of multicentric Castleman disease: A systematic review , 2021, European journal of haematology.

[7]  Sushila A. Shenoy,et al.  Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease. , 2021, Blood advances.

[8]  T. Takeuchi,et al.  IgG4-related disease and idiopathic multicentric Castleman's disease: confusable immune-mediated disorders. , 2021, Rheumatology.

[9]  M. Komatsu,et al.  IL-6 expression helps distinguish Castleman’s disease from IgG4-related disease in the lung , 2021, BMC Pulmonary Medicine.

[10]  B. Mahata,et al.  Revisiting steroidogenesis and its role in immune regulation with the advanced tools and technologies , 2021, Genes & Immunity.

[11]  T. Werner,et al.  Emerging role of 18F-FDG PET/CT in Castleman disease: a review , 2021, Insights into Imaging.

[12]  T. Yoshino,et al.  Pulmonary Manifestations of Plasma Cell Type Idiopathic Multicentric Castleman Disease: A Clinicopathological Study in Comparison with IgG4-Related Disease , 2020, Journal of personalized medicine.

[13]  Sijia Zhou,et al.  Idiopathic multicentric Castleman disease with Sjögren’s syndrome and secondary membranous nephropathy: a case report and review of the literature , 2020, BMC Nephrology.

[14]  M. Kawano,et al.  Comment on: HHV-8-negative multicentric Castleman disease patients with serological, histopathological and imaging features of IgG4-related disease: reply. , 2020, Rheumatology.

[15]  Andrew J. Oler,et al.  Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency. , 2020, Blood.

[16]  Sindhu R. Johnson,et al.  New Criteria for Lupus , 2020, Current Rheumatology Reports.

[17]  N. Hermann-Kleiter,et al.  Regulation of the germinal center response by nuclear receptors and implications for autoimmune diseases , 2020, The FEBS journal.

[18]  A. Dispenzieri,et al.  Overview of Castleman Disease. , 2020, Blood.

[19]  R. Suzuki,et al.  Epidemiological analysis of multicentric and unicentric Castleman disease and TAFRO syndrome in Japan , 2019, Journal of clinical and experimental hematopathology : JCEH.

[20]  Yuan Zhang,et al.  Recurrent PDGFRB mutations in unicentric Castleman disease , 2019, Leukemia.

[21]  D. Fajgenbaum.  Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. , 2018, Blood.

[22]  J. Rossi,et al.  International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. , 2018, Blood.

[23]  F. van Rhee,et al.  Treatment of Idiopathic Castleman Disease. , 2018, Hematology/oncology clinics of North America.

[24]  L. Vercellino,et al.  The full spectrum of Castleman disease: 273 patients studied over 20 years , 2018, British journal of haematology.

[25]  J. Rossi,et al.  International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. , 2017, Blood.

[26]  G. Schett,et al.  Paraneoplastic syndromes in rheumatology , 2014, Nature Reviews Rheumatology.

[27]  G. Hejblum,et al.  Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome , 2014, Arthritis & rheumatology.

[28]  L. Medeiros,et al.  Monoclonality and cytogenetic abnormalities in hyaline vascular Castleman disease , 2014, Modern Pathology.

[29]  C. Lohse,et al.  Cutaneous manifestations in patients with POEMS syndrome , 2013, International journal of dermatology.

[30]  K. Horton,et al.  Castleman disease: the great mimic. , 2011, Radiographics : a review publication of the Radiological Society of North America, Inc.

[31]  K. Nichols,et al.  X‐linked lymphoproliferative syndrome: a genetic condition typified by the triad of infection, immunodeficiency and lymphoma , 2011, British journal of haematology.